
Ardelyx (ARDX) is emerging as a compelling, yet risky, small-cap biotech opportunity. The company has made significant progress with two first-in-class therapies: IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) and XPHOZAH (tenapanor) for hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
Valued at $1.07 billion, Ardelyx stock has returned 542% over the last three years. With revenue growing and commercial execution improving, Ardelyx is positioning itself for potentially explosive growth.